ARCUTIS BIOTHERAPEUTICS, INC. Marketable Securities, Unrealized Gain (Loss)
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Marketable Securities, Unrealized Gain (Loss) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-02-28
- ARCUTIS BIOTHERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-12-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-09-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-06-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-03-31 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2022 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2021 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2020 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2019 was $0.00.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-02-22 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |